Background Evaluating trends in HCV treatment and prevalence is crucial for monitoring
elimination. We evaluated the change in current infection and treatment among people who …

Abstract Background and Aims We aimed to develop and validate machine learning
algorithms to predict direct‐acting antiviral (DAA) treatment failure among patients with HCV …

Background Patients from rural and low‐income households may have suboptimal access to
liver disease care, which may translate into worse HCC outcomes. The authors provide a …

Direct-acting antivirals (DAAs) achieve high hepatitis C virus (HCV) cure rates and are
forgiving to missed doses, but adherence–efficacy relationships have not been well defined …

Hepatitis C virus (HCV) is more prevalent among people with experience of severe mental
illness compared to the general population, due in part to higher levels of injecting drug use …

Background Direct‐acting anti‐virals (DAA) are highly effective for hepatitis C virus (HCV)
treatment, but perceived risks of medication non‐adherence may restrict access to care …

Abstract Introduction Hepatitis C virus (HCV) prevalence is high in the mental health
population. We sought to evaluate testing and treatment uptake for HCV following the …

Medicaid prior authorization (PA) policies for treatment of hepatitis C virus (HCV) with direct‐
acting antiviral (DAA) therapy are changing. We aimed to evaluate effects of changes in PA …

There are limited data examining the relationship between psychosocial factors and receipt
of direct‐acting antiviral (DAA) treatment among patients with hepatitis C in large health care …

Background People who inject drugs are the group at greatest risk of hepatitis C virus (HCV)
infection. The advent of new direct-acting antiviral (DAA) treatment provides opportunities for …